Pfizer, Boehringer Ingelheim Tap MacroGenics In Separate Deals
The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.
The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.